My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 205

    1.

    Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

    Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L.

    Ann Intern Med. 2000 Sep 19;133(6):401-10.PMID: 10975957 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

    Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

    Pediatrics. 2002 Feb;109(2):E25.PMID: 11826235 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

    Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

    J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8.PMID: 18285713 [PubMed - indexed for MEDLINE]Related articles

    4.

    Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA).

    Thiébaut R, Morlat P, Jacqmin-Gadda H, Neau D, Mercié P, Dabis F, Chêne G.

    AIDS. 2000 May 26;14(8):971-8.PMID: 10853978 [PubMed - indexed for MEDLINE]Related articles

    5.

    Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

    Van Vaerenbergh K.

    Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.PMID: 11813503 [PubMed - indexed for MEDLINE]Related articles

    6.

    Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

    Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group.

    J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50.PMID: 15097150 [PubMed - indexed for MEDLINE]Related articles

    7.

    Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection.

    Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine MD, Weiss L, Costagliola D.

    J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):284-92.PMID: 15980687 [PubMed - indexed for MEDLINE]Related articles

    8.

    Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

    García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

    J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.PMID: 11064501 [PubMed - indexed for MEDLINE]Related articles

    9.

    Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART.

    Nicastri E, Chiesi A, Angeletti C, Sarmati L, Palmisano L, Geraci A, Andreoni M, Vella S; Italian Antiretroviral Treatment Group (IATG).

    J Med Virol. 2005 Jun;76(2):153-60.PMID: 15834865 [PubMed - indexed for MEDLINE]Related articles

    10.

    Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.

    Gandhi T, Nagappan V, Cinti S, Wei W, Kazanjian P.

    Clin Infect Dis. 2007 Oct 15;45(8):1085-92. Epub 2007 Sep 14.PMID: 17879930 [PubMed - indexed for MEDLINE]Related articles

    11.

    Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.

    Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D.

    AIDS. 2004 Oct 21;18(15):2029-38.PMID: 15577624 [PubMed - indexed for MEDLINE]Related articles

    12.

    Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.

    MacArthur RD, Perez G, Walmsley S, Baxter JD, Mullin CM, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) 042/045; Canadian HIV Trials Network (CTN) 102 Protocol Teams.

    HIV Clin Trials. 2005 May-Jun;6(3):127-35.PMID: 16192247 [PubMed - indexed for MEDLINE]Related articles

    13.

    Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.

    Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD.

    J Infect Dis. 2001 May 1;183(9):1328-35. Epub 2001 Mar 29.PMID: 11294663 [PubMed - indexed for MEDLINE]Related articles

    14.

    Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

    Mocroft A, Gill MJ, Davidson W, Phillips AN.

    J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.PMID: 11035619 [PubMed - indexed for MEDLINE]Related articles

    15.

    Response to highly active antiretroviral therapy according to duration of HIV infection.

    Pezzotti P, Pappagallo M, Phillips AN, Boros S, Valdarchi C, Sinicco A, Zaccarelli M, Rezza G; Italian Seroconversion Study.

    J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):473-9.PMID: 11391168 [PubMed - indexed for MEDLINE]Related articles

    16.

    Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.

    Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, Wood E, Dong WW, Montaner JS, Harrigan PR.

    PLoS Med. 2006 Sep;3(9):e356.PMID: 16984218 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The use of efavirenz as a part of late rescue antiretroviral treatment.

    Manfredi R, Rizzo E, Calza L, Chiodo F.

    HIV Clin Trials. 2001 Sep-Oct;2(5):413-20.PMID: 11673816 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.

    Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, Tyrer M, Loveday C, Phillips AN, Johnson MA.

    AIDS. 2000 Jul 28;14(11):1545-52.PMID: 10983641 [PubMed - indexed for MEDLINE]Related articles

    19.

    Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.

    Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.

    AIDS. 2008 Nov 12;22(17):2371-80.PMID: 18981777 [PubMed - indexed for MEDLINE]Related articles

    20.

    Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

    Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

    Ann Intern Med. 2001 Dec 4;135(11):954-64.PMID: 11730396 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity